Client’s Testimonial:
“Overall, I’m very satisfied with the support I received.”
On July 23rd, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Fellow in the Field of Endocrine Cancer (Approval Notice).
General Field: Endocrine Cancer
Position at the Time of Case Filing: Postdoctoral Fellow
Country of Origin: Brazil
State of Residence at the Time of Filing: Texas
Approval Notice Date: July 23rd, 2025
Processing Time: 8 months, 25 days (Premium Processing Requested)
Case Summary:
We are proud to share the successful approval of an EB-2 NIW (National Interest Waiver) petition for a postdoctoral fellow originally from Brazil, whose cutting-edge work in the field of endocrine cancer is shaping the future of cancer diagnostics and therapy. At the time of filing, the client was conducting research at a renowned U.S. cancer institute, with a specialized focus on circulating tumor DNA (ctDNA) as a means of identifying molecular residual disease in cancer patients.
Transformative Research in Endocrine Oncology
The client’s primary research involves the validation and clinical application of ctDNA to detect residual disease and determine patient-specific therapeutic responses in endocrine cancers. This work significantly contributes to improving recurrence-free survival and overall outcomes for patients undergoing chemotherapy and immunotherapy. Her efforts include coordinating multi-institutional clinical trials, analyzing tumor genetic profiles, and optimizing treatment strategies for both malignant and benign adrenal lesions.
Credentials That Reflect Extraordinary Promise
With an extensive academic background in endocrinology and molecular biology, the client has authored 18 peer-reviewed journal articles, including several first-authored works, 20 conference abstracts, one preprint, and a book chapter. Her work has been published in high-impact journals such as Science Advances, Cancers, and The Lancet Oncology, underscoring the broad recognition of her contributions within the scientific community.
Her research has been cited 281 times, including several papers ranking in the top 1%, 10%, and 20% most-cited articles in her field for their publication years. In addition, she has contributed peer reviews to leading journals, demonstrating her standing as a trusted expert in endocrine oncology.
Expert Support and Endorsement
In support of her petition, one recommender wrote:
“Her work is pioneering in the integration of circulating tumor DNA with advanced cancer therapies, which has the potential to revolutionize our approach to detecting and managing residual disease. This is precisely the kind of work that elevates U.S. leadership in medical biotechnology and precision oncology.”
This testimony reflects the widespread acknowledgment of the client’s role in enhancing U.S. research capacity in cancer detection and treatment.
National Impact and Policy Relevance
We demonstrated in the petition that the client’s work directly advances critical and emerging technologies as outlined by the National Science and Technology Council. Her research in ctDNA analysis intersects with core national objectives such as public health improvement, bioinformatics innovation, and enhanced precision in therapeutic development—all areas deemed essential to national security and economic competitiveness.
A Strategic Win with NAILG
With the help of the North America Immigration Law Group (NAILG), the client filed her EB-2 NIW petition on October 28, 2024. The petition was approved on July 23, 2025—an efficient and timely success following our carefully crafted response to the unique details of her case. We are honored to have supported her in advancing her career and continuing research that holds great promise for cancer patients nationwide.
Histórias de Sucesso: NIW – Avanços no Diagnóstico do Câncer por Meio da Pesquisa em Oncologia Endócrina
Depoimento do Cliente:
“No geral, estou muito satisfeita com o apoio que recebi.”
Em 23 de julho de 2025, recebemos mais uma aprovação EB-2 NIW (National Interest Waiver) para uma Pesquisadora de Pós-Doutorado na área de Câncer Endócrino (Notificação de Aprovação).
Área Geral: Câncer Endócrino
Cargo no Momento do Protocolo: Pesquisadora de Pós-Doutorado
País de Origem: Brasil
Estado de Residência no Momento do Protocolo: Texas
Data da Notificação de Aprovação: 23 de julho de 2025
Tempo de Processamento: 8 meses e 25 dias (Processamento Premium Solicitado)
Resumo do Caso:
Temos orgulho em compartilhar a aprovação bem-sucedida de uma petição EB-2 NIW (National Interest Waiver) para uma pesquisadora de pós-doutorado originalmente do Brasil, cujo trabalho inovador na área de câncer endócrino está moldando o futuro do diagnóstico e da terapia oncológica. No momento do protocolo, a cliente conduzia pesquisa em um renomado instituto oncológico nos EUA, com foco especializado em DNA tumoral circulante (ctDNA) como meio de identificar doença residual molecular em pacientes com câncer.
Pesquisa Transformadora em Oncologia Endócrina
A pesquisa principal da cliente envolve a validação e aplicação clínica do ctDNA para detectar doença residual e determinar respostas terapêuticas específicas de cada paciente em casos de câncer endócrino. Esse trabalho contribui significativamente para melhorar a sobrevida livre de recorrência e os resultados gerais de pacientes submetidos a quimioterapia e imunoterapia. Seus esforços incluem coordenar ensaios clínicos multi-institucionais, analisar perfis genéticos tumorais e otimizar estratégias de tratamento para lesões adrenais malignas e benignas.
Credenciais que Refletem Potencial Extraordinário
Com uma sólida formação acadêmica em endocrinologia e biologia molecular, a cliente é autora de 18 artigos revisados por pares, incluindo vários como primeira autora, além de 20 resumos de conferências, um preprint e um capítulo de livro. Seu trabalho foi publicado em periódicos de alto impacto como Science Advances, Cancers e The Lancet Oncology, evidenciando o amplo reconhecimento de suas contribuições na comunidade científica.
Sua pesquisa recebeu 281 citações, incluindo vários artigos classificados entre o top 1%, 10% e 20% mais citados na área em seus respectivos anos de publicação. Ela também realizou revisões por pares para periódicos de destaque, demonstrando seu papel como especialista confiável em oncologia endócrina.
Apoio e Endosso de Especialistas
Em apoio à sua petição, uma das cartas de recomendação afirmou:
“Seu trabalho é pioneiro na integração do DNA tumoral circulante com terapias avançadas contra o câncer, o que tem o potencial de revolucionar nossa abordagem para detecção e manejo de doença residual. Este é exatamente o tipo de trabalho que fortalece a liderança dos EUA em biotecnologia médica e oncologia de precisão.”
Esse testemunho reflete o amplo reconhecimento do papel da cliente em fortalecer a capacidade de pesquisa dos EUA na detecção e tratamento do câncer.
Impacto Nacional e Relevância para Políticas Públicas
Demonstramos na petição que o trabalho da cliente avança diretamente tecnologias críticas e emergentes delineadas pelo National Science and Technology Council. Sua pesquisa em análise de ctDNA se conecta a objetivos centrais nacionais, como melhoria da saúde pública, inovação em bioinformática e maior precisão no desenvolvimento terapêutico — áreas consideradas essenciais para a segurança nacional e competitividade econômica.
Uma Vitória Estratégica com a NAILG
Com o apoio da North America Immigration Law Group (NAILG), a cliente protocolou sua petição EB-2 NIW em 28 de outubro de 2024. A aprovação ocorreu em 23 de julho de 2025 — um sucesso eficiente e oportuno após nossa resposta cuidadosamente estruturada aos detalhes únicos de seu caso. Temos a honra de ter apoiado sua trajetória e o avanço de pesquisas que oferecem grande promessa para pacientes com câncer em todo o país.
North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).
Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend
With nearly 64,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.
We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours
With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.
Vast Majority of Clients Came to Us Because of Referrals
For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to nearly 64,000 in 2025.
Track Record of Success EB-1 and NIW Approvals
Approval Notices: https://www.wegreened.com/eb1_niw_approvals
Success Stories: https://www.wegreened.com/blog/
Website: www.wegreened.com
Free evaluation: https://www.wegreened.com/Free-Evaluation
Tel: 888.666.0969 (Toll Free)
To see more clients’ testimonials and approvals, please refer to:
To Learn More About Your Options CLICK HERE
Copyright © North America Immigration Law Group – WeGreened.com, All Rights Reserved.